CD28 and B7 family reagents in clinical trials
Approach . | Company/sponsor . | Reference(s) . |
|---|---|---|
| Costimulatory blockade | ||
| CTLA-4-Ig: rheumatoid arthritis (phase 3) and multiple sclerosis (phase 1) | Bristol-Myers Squibb, New York, NY | 126 |
| Repligen, Waltham, MA | ||
| LEA29Y, second generation CTLA-4-Ig: kidney allografts (phase 2) | Bristol-Myers Squibb, New York, NY | 127 |
| Anti-CD80/86 mAbs: prevention of GVHD (phase 1) | Dana Farber Cancer Institute, Boston, MA | 3, 128 |
| Anti-CD80 mAb: psoriasis (phase 1/2) | Biogen Idec, Cambridge, MA | |
| Costimulatory augmentation | ||
| Anti-CTLA-4 mAb: various tumors (phase 2) | Medarex, Princeton, NJ | 117, 129 |
| Pfizer, New York, NY | ||
| B7-modified tumor cells (phase 1, various) | NCI, Bethesda, MD | 130 |
| Anti-CD3/CD28 activated T cells: leukemia and renal cell carcinoma (phase 2) | Xcyte/NCI, Seattle, WA | 15, 131 |
| Recombinant vaccinia virus expressing B7-1 (phase 2) | Therion/NCI, Bayshore, NY | 132 |
| CC-5013 (IMiD3), CD28 pathway augmentation: myeloma (phase 2 and 3) | Celgene, Warren, NJ | 133 |
| CD28-superMAB (superagonistic CD28 antibody): immune restoration (preclinical) | TeGenero, Würzburg, Germany | 134 |
Approach . | Company/sponsor . | Reference(s) . |
|---|---|---|
| Costimulatory blockade | ||
| CTLA-4-Ig: rheumatoid arthritis (phase 3) and multiple sclerosis (phase 1) | Bristol-Myers Squibb, New York, NY | 126 |
| Repligen, Waltham, MA | ||
| LEA29Y, second generation CTLA-4-Ig: kidney allografts (phase 2) | Bristol-Myers Squibb, New York, NY | 127 |
| Anti-CD80/86 mAbs: prevention of GVHD (phase 1) | Dana Farber Cancer Institute, Boston, MA | 3, 128 |
| Anti-CD80 mAb: psoriasis (phase 1/2) | Biogen Idec, Cambridge, MA | |
| Costimulatory augmentation | ||
| Anti-CTLA-4 mAb: various tumors (phase 2) | Medarex, Princeton, NJ | 117, 129 |
| Pfizer, New York, NY | ||
| B7-modified tumor cells (phase 1, various) | NCI, Bethesda, MD | 130 |
| Anti-CD3/CD28 activated T cells: leukemia and renal cell carcinoma (phase 2) | Xcyte/NCI, Seattle, WA | 15, 131 |
| Recombinant vaccinia virus expressing B7-1 (phase 2) | Therion/NCI, Bayshore, NY | 132 |
| CC-5013 (IMiD3), CD28 pathway augmentation: myeloma (phase 2 and 3) | Celgene, Warren, NJ | 133 |
| CD28-superMAB (superagonistic CD28 antibody): immune restoration (preclinical) | TeGenero, Würzburg, Germany | 134 |